Immunocore Holdings plc Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Immunocore Holdings plc (IMCR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.58 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 190.05K shares, a 9.56% decline year-over-year.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 1.39M shares, a 9.25% decline year-over-year.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 25.71K shares, a 11.95% decline year-over-year.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 28.50K shares, a 24.64% decline year-over-year.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 1.79M shares, a 68.76% increase from fiscal 2024.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.06M shares, a 24.46% increase from fiscal 2023.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 853.86K shares, a 43.36% decline from fiscal 2022.
- Immunocore Holdings plc share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.51M shares, a 67.94% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 190.05K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 1.58M shares 10-Q · filed 2026-08-06 | 1.60M shares derived: sum of 3 quarters · filed 2026-08-06 | 1.63M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 1.39M shares 10-Q · filed 2026-05-06 | 1.41M shares derived: sum of 2 quarters · filed 2026-05-06 | 1.44M shares derived: sum of 3 quarters · filed 2026-05-06 | 1.65M shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 25.71K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | 54.21K shares derived: sum of 2 quarters · filed 2026-02-25 | 264.36K shares derived: sum of 3 quarters · filed 2026-02-25 | 1.79M shares 10-K · filed 2026-02-25 |
| 2025-09-30 | 28.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 238.64K shares derived: sum of 2 quarters · filed 2025-11-06 | 1.77M shares 10-Q · filed 2025-11-06 | 1.80M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 210.15K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 1.74M shares 10-Q · filed 2025-08-07 | 1.77M shares derived: sum of 3 quarters · filed 2025-08-07 | 1.81M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 1.53M shares 10-Q · filed 2025-05-07 | 1.56M shares derived: sum of 2 quarters · filed 2025-05-07 | 1.60M shares derived: sum of 3 quarters · filed 2025-05-07 | 1.72M shares derived: sum of 4 quarters · filed 2025-05-07 |
| 2024-12-31 | 29.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | 67.01K shares derived: sum of 2 quarters · filed 2025-02-26 | 194.28K shares derived: sum of 3 quarters · filed 2025-02-26 | 1.06M shares 10-K · filed 2025-02-26 |
| 2024-09-30 | 37.81K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 165.07K shares derived: sum of 2 quarters · filed 2024-11-06 | 1.03M shares 10-Q · filed 2024-11-06 | |
| 2024-06-30 | 127.26K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 995.73K shares 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | 868.47K shares 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | 853.86K shares 10-K · filed 2024-02-28 | |||
| 2022-12-31 | 1.51M shares 10-K · filed 2024-02-28 | |||
| 2021-12-31 | 4.70M shares 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |